Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

Published Date: 24 Jun 2024

No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

2.

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

3.

Chemo causes lasting physical decline in breast cancer survivors

4.

MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA

5.

BMI is linked to heart damage from chemotherapy in breast cancer patients.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot